Contribution of Sex Steroids in Management of Tall Stature: Is It Effective or Not?
Authors' conclusion
Sex difference, sex steroid dosage, differences in treatment duration and differences in BA measurement method, PAH method, BA and chronological age at the start of treatment may all influence the therapy response. Shortcomings about these influences can be overcome in future prospective studies with a larger sample size.
Study context
- Population
- Tall children (familial tall stature, constitutional advance of growth or Marfan syndrome) treated with low-dose sex steroids
- Participants
- 22 children
- Exposure
- Final height vs predicted adult height after low-dose sex steroids
- Outcome
- Final height vs predicted adult height (PAH; Bayley-Pinneau and Tanner-Whitehouse mark II methods)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Final height vs PAH
- Girls: final height significantly lower than predicted height
- Boys: final height not significantly lower than predicted height
- Marfan syndrome: final height lower only than Tanner-Whitehouse (TW) prediction, not Bayley-Pinneau (BP)
- Non-Marfan: final height significantly lower than both predicted heights
Observational data: associations, not effects.
Further findings
Height SDS over time
- Decrease in height SDS, not statistically significant
Treatment start at early bone age (<10 years)
- Did not affect last height SDS or difference between predicted and final height
Original publication
Contribution of Sex Steroids in Management of Tall Stature: Is It Effective or Not? Horm Res Paediatr. Published 29 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →